Event Details

The Immatics team will attend the 22^nd International Congress of The Society for Melanoma Research in Amsterdam.

Oral Presentation:

Date: October 27, 2025
Session: Plenary Session 6 – Rare and Challenging Melanomas
Time: 2:40 - 2:55 pm CET
Title: Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial
Presenter: Sapna Patel, MD, Professor of Medicine, University of Colorado Cancer Center

Date: October 27, 2025
Session: Plenary Session 7 – Understanding and Optimizing the Immunotherapy Response (II)
Time: 4:50 - 5:05 pm CET
Title: IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, demonstrated broad organ penetration in patients with heavily pretreated advanced or metastatic melanoma in a phase 1 trial
Presenter: Prof. Dr. med. Martin Wermke,  University Hospital Dresden

Poster Presentation:
Title: #241 (SUPRAME TiP): A Phase 3 trial evaluating IMA203 TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
 

For more information, visit the congress website by clicking here.